期刊档案 · ONCOLOGY
Memo-Magazine of European Medical Oncology
ISSN 1865-5041 · eISSN 1865-5076 · Springer Nature · 4 issues per year
Memo-Magazine of European Medical Oncology 中科院 医学 4区（2025 年升级版），影响因子 0.6（官网公布），混合开放获取，APC 约 4,790 美元，近 24 个月 74 篇文章投稿到接收中位 61 天，2025 年发文 75 篇，ESCI、Scopus 收录。
研究范围
研究范围与定位
Memo-Magazine of European Medical Oncology 由 Springer Nature 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Lymphoma Diagnosis and Treatment、Lung Cancer Treatments and Mutations、Chronic Lymphocytic Leukemia Research 等主题的论文，这 3 个主题约占 21.8%，主导子领域为 Oncology。（根据 OpenAlex 主题统计与中科院分区数据生成）
memo is the Official Journal of the Central European Cooperative Oncology Group (CECOG) and The Austrian Society of Haematology and Oncology (OeGHO). The focus of the journal "magazine of european medical oncology – memo" is to offer a professional review on current research and development in the field of hematology and oncology relevant for daily practice. Therefore, memo includes editorials and comments, peer-reviewed original reports, short reviews, case reports and controversies, articles explaining the biology of neoplasia and congress reports including qualified comments. As a European journal memo aims at highlighting the local peculiarities of various regions and at being a forum for the presentation of ongoing clinical and basic research.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：ONCOLOGY
主编 Wolfgang Hilbe出版商官网
编委会国家分布：未见中国大陆编委；主要国家 奥地利 41、瑞士 5、波兰 4、希腊 4、罗马尼亚 4（共 84 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Lymphoma Diagnosis and TreatmentMedicine7.7%
- Lung Cancer Treatments and MutationsMedicine7.3%
- Chronic Lymphocytic Leukemia ResearchMedicine6.8%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.8%
- Acute Myeloid Leukemia ResearchMedicine4.9%
- Gastric Cancer Management and OutcomesMedicine4.9%
- Colorectal Cancer Treatments and StudiesMedicine4.8%
- Cancer Immunotherapy and BiomarkersMedicine4.6%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 肿瘤学ONCOLOGY | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 肿瘤学ONCOLOGY | 4 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
ESCIScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
Embase出版商官网
其他：Google Scholar、EBSCO、ProQuest、Dimensions、CNKI、Baidu、Naver、OCLC、Portico、CLOCKSS、Semantic Scholar
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子（出版商公布） 2025
- 0.6出版商官网 ·
- 五年影响因子（出版商公布） 2025
- 0.4出版商官网 ·
- CiteScore 2026-06
- 1.2LetPub ·
- SJR 2026-06
- 0.28LetPub ·
- SNIP 2026-06
- 0.17LetPub ·
- h-index
- 26OpenAlex ·
- i10-index
- 82OpenAlex ·
- 两年平均被引
- 0.77OpenAlex ·
- 自引率
- 0%LetPub ·
- Gold OA 文章占比
- 62.92%LetPub ·
发文规模
- 年文章数
- 65LetPub ·
- 年下载量（出版商公布） 2025
- 249,900出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 1,415 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 38 | 28 | 6 |
| 2025 | 75 | 48 | 45 |
| 2024 | 68 | 48 | 88 |
| 2023 | 87 | 70 | 103 |
| 2022 | 75 | 48 | 113 |
| 2021 | 110 | 82 | 439 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 Crossref 登记的稿件日期 · 至
61 天投稿到接收中位数 · P25–P75 39 天 – 79 天
- 接收到上线
- 中位数 31 天（90 篇）
- 投稿到上线
- 中位数 89 天
- 样本
- 74 篇有投稿与接收日期的文章（窗口内共 132 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 投稿到首次决定
- 1 天出版商官网 ·
- 评审方式
- 双盲同行评审出版商官网
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
混合开放获取LetPub
订阅期刊，作者可付费选择开放获取发表。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| OpenAlex | USD 4,790 / EUR 3,690 / GBP 2,990 | — | — |
混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点9 项，摘自作者指南
- 摘要
- 150–250 词
- 关键词
- ≥ 4 个
- 正文篇幅
- ≤ 2,000 词
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- 稿件模板
- 提供 LaTeX 与 Word 模板
- 推荐审稿人
- 可选
- Highlights（研究亮点）
- 可选
- 图文摘要
- 可选
- 投稿信（Cover letter）
- 必须提供
接收的文章类型18 种，含篇幅限制
- case reportEditorials are in general invited by the Editor-in-Chief with the intention to accompany an accepted manuscript and should contain no more than 500 words in len…正文 ≤ 1,000 词
- case reportsCase reports should include a concise literature review and are limited to 1,000 words and 20 citations. Images are welcome.未说明篇幅
- comments on a specific articleComments on a specific article are limited to 500 words and 5 citations.未说明篇幅
- comments on important abstractsComments on important abstracts presented at leading meetings or congresses are appreciated (limited to 300 words, 2 citations).未说明篇幅
- controversiesControversies should focus on one single topic of interest and are limited to 1,000 words and 20 citations.未说明篇幅
- correspondenceEditorials are in general invited by the Editor-in-Chief with the intention to accompany an accepted manuscript and should contain no more than 500 words in len…未说明篇幅
- correspondence (letters to the editor)Correspondence (Letters to the Editor) are welcome (limited to 300 words).未说明篇幅
- editorialEditorials are in general invited by the Editor-in-Chief with the intention to accompany an accepted manuscript and should contain no more than 500 words in len…未说明篇幅
- editorialsEditorials are in general invited by the Editor-in-Chief with the intention to accompany an accepted manuscript and should contain no more than 500 words in len…未说明篇幅
- letters to the editorEditorials are in general invited by the Editor-in-Chief with the intention to accompany an accepted manuscript and should contain no more than 500 words in len…未说明篇幅
- literature reviewEditorials are in general invited by the Editor-in-Chief with the intention to accompany an accepted manuscript and should contain no more than 500 words in len…未说明篇幅
- original reportsOriginal reports are limited to 2,000 words of body text, excluding the abstract, references, figures, and tables. Original Reports are limited to six total fig…未说明篇幅
- perspectivesPerspectives are written only at the invitation of the Editor-in-Chief and Editorial Board.未说明篇幅
- reviewEditorials are in general invited by the Editor-in-Chief with the intention to accompany an accepted manuscript and should contain no more than 500 words in len…未说明篇幅
- review articleEditorials are in general invited by the Editor-in-Chief with the intention to accompany an accepted manuscript and should contain no more than 500 words in len…未说明篇幅
- short reviewEditorials are in general invited by the Editor-in-Chief with the intention to accompany an accepted manuscript and should contain no more than 500 words in len…正文 ≤ 1,500 词
- special articlesSpecial articles may include, but are not limited to, guidelines, summaries of consensus meetings, and other scholarly communications.未说明篇幅
- supplementsSupplements: Abstracts of congresses or reviews of presentations and lectures given at meetings or congresses are moderated by guest editors.未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、试验注册 / 报告规范
- AI 使用 Generative AI Images
请核查Springer关于生成式AI图像的政策，并确保您的工作遵守其中所述的原则。 模型中文摘要
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein.
原文 ↗出版商官网 ·- 作者资格 Authorship principles
这些指南描述了作者身份原则和良好作者实践， prospective authors should adhere to. 作者身份澄清：期刊和出版商假定所有作者同意内容，且在提交前已获得工作所在机构/组织负责当局的同意。出版商不规定何种贡献可获作者身份。 模型中文摘要
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
原文 ↗出版商官网 ·- 利益冲突 Disclosures and declarations
所有作者被要求提供资金来源、财务或非财务利益、涉及人类和/或动物研究的伦理委员会批准、涉及人类受试者的知情同意，以及涉及动物研究的动物福利声明（如适用）。 模型中文摘要
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
原文 ↗出版商官网 ·- 数据可用性
所有作者被要求确保所有数据和材料以及软件应用或自定义代码支持其已发表的主张并符合领域标准。 模型中文摘要
All authors are requested to make sure that all data and materials as well as software application or custom code support their published claims and comply with field standards.
原文 ↗出版商官网 ·- 出版伦理 Compliance with Ethical Standards
为确保客观性和透明度，作者应提供资金来源、潜在利益冲突（财务或非财务）、涉及人类受试者的知情同意以及涉及动物研究的动物福利声明等信息，并在提交时以“Compliance with Ethical Standards”为标题的单独章节中包含适用声明。 模型中文摘要
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
原文 ↗出版商官网 ·- 许可与版权 Copyright
Open Choice文章无需转让版权，版权仍归作者所有；选择开放获取时，作者同意在知识共享许可下发表文章。 模型中文摘要
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide.
原文 ↗出版商官网 ·- 开放获取 Open access publishing
欲了解在memo - Magazine of European Medical Oncology以开放获取方式发表作品的更多信息（包括费用、资助和许可），请访问其开放获取出版页面。 模型中文摘要
To find out more about publishing your work Open Access in memo - Magazine of European Medical Oncology, including information on fees, funding and licences, visit our Open access publishing page. Back to top
原文 ↗出版商官网 ·- 同行评审
在Memo – Magazine of European Medical Oncology，稿件录用基于工作的原创性、质量和优先性。 模型中文摘要
Manuscript acceptance in Memo – Magazine of European Medical Oncology is based on originality, quality and priority of the work.
原文 ↗出版商官网 ·- 试验注册 / 报告规范 Clinical Trial Registration
世界卫生组织对临床试验的定义是“任何前瞻性地将人类受试者或人群分配到一个或多个健康相关干预措施以评估健康结果影响的研究”。 模型中文摘要
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Springer Nature
- 出版周期
- 4 issues per year
- ISSN
- 1865-5041
- 电子版 ISSN
- 1865-5076
- 学会 / 主办单位
- Central European Cooperative Oncology Group
- 官网最新一期
- Volume 19, Issue 2（2026 年 5 月）
常见问题
关于 Memo-Magazine of European Medical Oncology 的常见问题
Memo-Magazine of European Medical Oncology 是中科院几区期刊？
2025 年升级版分区表中，Memo-Magazine of European Medical Oncology 为医学 4区，小类 肿瘤学 4 区。2026 年新锐版分区表中为医学 4区。不同版本与大小类分区不能混用。
Memo-Magazine of European Medical Oncology 的影响因子是多少？
期刊官网公布的影响因子为 0.6（2025 年度），属期刊自述数据，LetPub 暂无该刊的影响因子记录，CiteScore 为 1.2，h-index 为 26。
Memo-Magazine of European Medical Oncology 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）74 篇已发表文章登记的日期，投稿到接收的中位数为 61 天（四分位 39–79 天）。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Memo-Magazine of European Medical Oncology 的投稿格式要求是什么？
据期刊作者指南：摘要：150–250 词；关键词：≥ 4 个；正文篇幅：≤ 2,000 词；参考文献格式：顺序编码制（按引用顺序编号）；稿件模板：提供 LaTeX 与 Word 模板；推荐审稿人：可选；Highlights：可选；图文摘要：可选；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Memo-Magazine of European Medical Oncology 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 84 位编委中，没有中国大陆学者；人数最多的国家是 奥地利（41 位）、瑞士（5 位）、波兰（4 位）。统计按编委会页面列出的机构国家计，仅供参考。
Memo-Magazine of European Medical Oncology 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Memo-Magazine of European Medical Oncology 被 ESCI、Scopus 收录。期刊官网自述还被 Embase 收录，该清单未与各数据库逐一核对。
Memo-Magazine of European Medical Oncology 是开放获取期刊吗？版面费多少？
Memo-Magazine of European Medical Oncology 为混合开放获取。选择开放获取发表时APC 约 4,790 美元。
来源与更新
本页事实来自 LetPub、OpenAlex、出版商官网；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。